SPL84

DRUG2 trials

Sponsors

SpliSense Ltd.

Conditions

Cystic Fibrosis

Phase 1

Safety, Tolerability, and Pharmacokinetics of SPL84 in Healthy Volunteers

CompletedNCT06217952

SpliSense Ltd.Cystic Fibrosis

Start: 2023-02-05End: 2023-08-06Updated: 2024-01-23

Phase 2

Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of SPL84 in Patients With Cystic Fibrosis

RecruitingNCT06429176

SpliSense Ltd.Cystic Fibrosis

Start: 2024-06-24End: 2027-12-31Target: 64Updated: 2026-05-14